Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 7/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24876304 | 0.82 | KRAS (0.35) | KRAS | |
| SCHEMBL24876392 | 0.82 | KRAS (0.35) | KRAS | |
| SCHEMBL25066432 | 0.81 | KRAS (0.34) | KRAS | |
| SCHEMBL24543191 | 0.80 | KRAS (0.38) | KRAS | |
| SCHEMBL25445889 | 0.80 | KRAS (0.34) | KRASKMT2A | |
| SCHEMBL25066398 | 0.80 | KRAS (0.34) | KRAS | |
| SCHEMBL30501887 | 0.76 | VNN1 (0.39) | KRASVNN1DPP4DPP7 | |
| SCHEMBL30501721 | 0.74 | VNN1 (0.38) | VNN1DPP4DPP7PREP | |
| SCHEMBL14808879 | 0.73 | VNN1 (0.42) | VNN1DPP4DPP7PREP | |
| SCHEMBL28793584 | 0.73 | VNN1 (0.42) | VNN1DPP4DPP7PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030884-B2 | Pyrazoloquinoline KRAS inhibitors | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230143938-A1 | PYRAZOLOQUINOLINE KRAS INHIBITORS | INCYTE CORPORATION | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143938-A1 | PYRAZOLOQUINOLINE KRAS INHIBITORS | KRAS, NRAS, HRAS | KRAS 1/4885VNN1 4178/4885KMT2A 2953/4885 |
| US-12030884-B2 | Pyrazoloquinoline KRAS inhibitors | KRAS, NRAS, HRAS | KRAS 1/4885VNN1 4178/4885KMT2A 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.